AKT1 and chronic obstructive pulmonary disease: We used an in vitro study to confirm that treatment with TBFS drug-containing serum improves glucocorticoid resistance in COPD via the downregulation of the PI3K-Akt signaling pathway and promotion of GRα expression (Figure 10).